DE602006016085D1 - Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor - Google Patents
Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktorInfo
- Publication number
- DE602006016085D1 DE602006016085D1 DE602006016085T DE602006016085T DE602006016085D1 DE 602006016085 D1 DE602006016085 D1 DE 602006016085D1 DE 602006016085 T DE602006016085 T DE 602006016085T DE 602006016085 T DE602006016085 T DE 602006016085T DE 602006016085 D1 DE602006016085 D1 DE 602006016085D1
- Authority
- DE
- Germany
- Prior art keywords
- egfr kinase
- methods
- kinase inhibitors
- inhibitors
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66254505P | 2005-03-16 | 2005-03-16 | |
US67182105P | 2005-04-15 | 2005-04-15 | |
PCT/US2006/009403 WO2006101925A2 (en) | 2005-03-16 | 2006-03-16 | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006016085D1 true DE602006016085D1 (de) | 2010-09-23 |
Family
ID=36586095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006016085T Active DE602006016085D1 (de) | 2005-03-16 | 2006-03-16 | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
Country Status (7)
Country | Link |
---|---|
US (3) | US8093011B2 (de) |
EP (1) | EP1861715B1 (de) |
JP (1) | JP5085529B2 (de) |
AT (1) | ATE477495T1 (de) |
CA (1) | CA2601157A1 (de) |
DE (1) | DE602006016085D1 (de) |
WO (1) | WO2006101925A2 (de) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017321B2 (en) * | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
EP2949764B1 (de) | 2004-05-27 | 2018-04-11 | The Regents of The University of Colorado | Verfahren zur vorhersage der klinischen resultate in bezug auf epidermale wachstumsfaktor-rezeptorhemmer von krebspatienten |
KR20080003334A (ko) * | 2005-03-11 | 2008-01-07 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제 |
EP1861715B1 (de) | 2005-03-16 | 2010-08-11 | OSI Pharmaceuticals, Inc. | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
ES2374450T3 (es) * | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
CA2669675A1 (en) * | 2006-11-10 | 2008-05-15 | Syndax Pharmaceuticals, Inc. | Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer |
KR100934706B1 (ko) * | 2006-12-07 | 2009-12-31 | 재단법인서울대학교산학협력재단 | Tm4sf5의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물 |
WO2008109075A2 (en) * | 2007-03-05 | 2008-09-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
JP5240739B2 (ja) * | 2007-04-13 | 2013-07-17 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
JP5352585B2 (ja) * | 2007-07-13 | 2013-11-27 | ネステク ソシエテ アノニム | 抗体アレイを用いた肺癌治療のための薬剤選択 |
WO2009015203A1 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
WO2009015237A1 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
ES2477294T3 (es) * | 2007-08-13 | 2014-07-16 | Baxter International Inc | Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson |
KR20100037639A (ko) | 2007-08-14 | 2010-04-09 | 에프. 호프만-라 로슈 아게 | Egfr 억제제를 이용한 치료에 대한 예측 마커 |
AU2008286333B2 (en) * | 2007-08-14 | 2013-11-14 | F. Hoffmann-La Roche Ag | Predictive marker for EGFR inhibitor treatment |
KR20100037637A (ko) | 2007-08-14 | 2010-04-09 | 에프. 호프만-라 로슈 아게 | Egfr 억제제 치료에 대한 예측 마커 |
WO2009021675A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
US20090309617A1 (en) * | 2007-08-24 | 2009-12-17 | Ye Fang | Biosensor antibody functional mapping |
EP2036576A1 (de) * | 2007-09-17 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | ED-B-Fibronektin als Stratifizierungsmarker für Antitumormittel |
EP2208066A2 (de) * | 2007-10-03 | 2010-07-21 | OSI Pharmaceuticals, Inc. | Biologische marker zur vorhersage der antikrebs-antwort auf insulinähnlicher-wachstumsfaktor-1-rezeptorkinase-inhibitoren |
AU2008307634A1 (en) * | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8187800B2 (en) | 2007-10-15 | 2012-05-29 | Precision Therapeutics, Inc. | Methods for selecting active agents for cancer treatment |
WO2009058895A1 (en) * | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
EP2071336A1 (de) * | 2007-12-13 | 2009-06-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Serumproteom zum Finden von diagnostischen Markern und zur Überwachung des therapeutischen Eingriffs bei der Behandlung von Leberzellenkarzinom |
TW200940064A (en) * | 2008-03-06 | 2009-10-01 | Genentech Inc | Combination therapy with C-MET and EGFR antagonists |
US7951549B2 (en) * | 2008-03-07 | 2011-05-31 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US7998688B2 (en) * | 2008-03-07 | 2011-08-16 | OSI Pharmaceuticals, LLC | Inhibition of EMT induction in tumor cells by anti-cancer agents |
WO2009126310A2 (en) * | 2008-04-10 | 2009-10-15 | Massachusetts Institute Of Technology | Methods for identification and use of agents targeting cancer stem cells |
US20100311084A1 (en) * | 2008-05-14 | 2010-12-09 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
CA2721687A1 (en) * | 2008-05-14 | 2009-11-19 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
EP2400990A2 (de) * | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (de) * | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen |
JP2012519282A (ja) * | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
US20120095030A1 (en) * | 2009-04-17 | 2012-04-19 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
EP2419177A1 (de) * | 2009-04-17 | 2012-02-22 | OSI Pharmaceuticals, LLC | Biologische marker zur vorhersage einer anti-krebs-antwort auf epidermale wachstumsfaktor-rezeptor-kinase-inhibitoren |
US8323883B1 (en) | 2009-10-09 | 2012-12-04 | Cold Spring Harbor Laboratory | Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors |
US7947653B1 (en) | 2009-10-09 | 2011-05-24 | Cold Spring Harbor Laboratory | Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers |
US20110217309A1 (en) * | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20120095029A1 (en) * | 2010-10-15 | 2012-04-19 | Hoffmann-La Roche Inc. | Ipp complex as marker for erlotinib treatment |
WO2012135841A2 (en) * | 2011-04-01 | 2012-10-04 | Board Of Regents, The University Of Texas System | Emt signatures and predictive markers and method of using the same |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
KR20140044341A (ko) * | 2011-06-02 | 2014-04-14 | 알막 다이아그노스틱스 리미티드 | 암에 대한 분자적 진단 검사 |
CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
BR112014007569A2 (pt) | 2011-09-30 | 2017-04-18 | Genentech Inc | marcadores de metilação diagnósticos fenótipo epitelial ou mesenquimal e a resposta ao inibidor da quinase de egfr em tumores ou células tumorais |
US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
US20150125857A1 (en) | 2012-02-28 | 2015-05-07 | Novartis Ag | CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |
WO2013146993A1 (ja) * | 2012-03-28 | 2013-10-03 | 株式会社オンチップ・バイオテクノロジーズ | 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット |
SG11201408651TA (en) | 2012-06-27 | 2015-01-29 | Berg Llc | Use of markers in the diagnosis and treatment of prostate cancer |
WO2014043633A1 (en) * | 2012-09-17 | 2014-03-20 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
CN105263915B (zh) | 2012-11-21 | 2019-04-12 | 安吉奥斯医药品有限公司 | 谷氨酰胺酶抑制剂及使用方法 |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
SG11201504023SA (en) | 2012-12-03 | 2015-06-29 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
US9782075B2 (en) | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
US11089959B2 (en) | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
JP2017505301A (ja) * | 2014-01-08 | 2017-02-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 転移性播種を予防又は低減するための方法及び医薬組成物 |
CA2943339A1 (en) | 2014-03-21 | 2015-09-24 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
WO2015168255A1 (en) | 2014-04-29 | 2015-11-05 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
EP4242329A3 (de) | 2014-12-08 | 2023-10-25 | Berg LLC | Verwendung von markern einschliesslich filamin a bei der diagnose und behandlung von prostatakrebs |
EP3392334A4 (de) | 2015-12-18 | 2019-10-30 | Zeon Corporation | Verfahren zur herstellung von adhärenten, an suspensionskultur akklimatisierte zellen, verfahren zur induzierung des epithelial-mesenchymalen übergangs bei adhärenten epithelzellen und verwendung für verfahren |
JP6789512B2 (ja) * | 2016-05-10 | 2020-11-25 | 学校法人日本医科大学 | 肺癌治療のための抗癌剤の効果の検査法 |
JP7112660B2 (ja) * | 2018-03-13 | 2022-08-04 | アイ2ディーエックス インコーポレイテッド | 個別化医療における情報の電子配信 |
CN113312056B (zh) * | 2021-06-16 | 2022-04-19 | 浪潮云信息技术股份公司 | angular大型集成项目的国际化实现方法、电子设备及存储介质 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
US5925519A (en) * | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
ATE292623T1 (de) | 1997-05-07 | 2005-04-15 | Sugen Inc | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
ID23978A (id) | 1997-11-11 | 2000-06-14 | Pfizer Prod Inc | Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker |
NZ508815A (en) | 1998-05-29 | 2005-02-25 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
ES2161612B1 (es) | 1999-07-01 | 2002-06-01 | Consejo Superior Investigacion | Procedimiento para identificar un compuesto que inhiba la funcion represora de snail. |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
JP2005523688A (ja) | 2002-01-18 | 2005-08-11 | ブリストル−マイヤーズ スクイブ カンパニー | タンパク質チロシンキナーゼおよび/またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定 |
EP1918386B9 (de) | 2002-03-13 | 2012-08-08 | Genomic Health, Inc. | Genexpressionsprofilierung in einer Biopsie unterzogenem Tumorgewebe |
WO2003101491A1 (fr) * | 2002-06-03 | 2003-12-11 | Mitsubishi Pharma Corporation | Moyens preventifs et/ou therapeutiques destines a des sujets presentant l'expression ou l'activation de her2 et/ou egfr |
BR0311814A (pt) | 2002-06-05 | 2005-03-15 | Cedars Sinai Medical Center | Método de tratar câncer empregando inibidores de cinase |
WO2004000102A2 (en) | 2002-06-19 | 2003-12-31 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
EP1570080A4 (de) | 2002-11-15 | 2006-03-01 | Genomic Health Inc | Genexpressionsprofilierung einer egfr-positiven krebserkrankung |
CA2512536A1 (en) | 2003-01-08 | 2004-07-29 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
WO2004065602A1 (es) | 2003-01-17 | 2004-08-05 | Universidad Autónoma de Madrid | Procedimiento para identificar la transición epitelio-mesenquimal de células mesoteliales (temcm) e identificar compuestos moduladores de temcm, composiciones farmacéuticas y su uso en el diagnóstico y tratamiento de enfermedades que cursan con temcm |
EP1590487A2 (de) | 2003-02-06 | 2005-11-02 | Genomic Health, Inc. | Genexpressionsmarker für die antwort auf egfr-inhibitormedikamente |
JP3762975B2 (ja) * | 2003-03-18 | 2006-04-05 | 学校法人慶應義塾 | 単球由来多能性細胞momc |
WO2004111273A2 (en) | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
EP1664716A4 (de) | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | Krebs-biomarker |
JP2007537717A (ja) | 2004-01-07 | 2007-12-27 | ブリストル−マイヤーズ スクイブ カンパニー | 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法 |
US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
WO2005094332A2 (en) | 2004-03-26 | 2005-10-13 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer |
WO2005107803A2 (en) | 2004-05-06 | 2005-11-17 | Vernalis Plc | Methods of determining the prognosis and treatment of subjects with lung cancer |
EP2949764B1 (de) | 2004-05-27 | 2018-04-11 | The Regents of The University of Colorado | Verfahren zur vorhersage der klinischen resultate in bezug auf epidermale wachstumsfaktor-rezeptorhemmer von krebspatienten |
KR20080003334A (ko) | 2005-03-11 | 2008-01-07 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제 |
EP1861715B1 (de) | 2005-03-16 | 2010-08-11 | OSI Pharmaceuticals, Inc. | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
AU2006287175A1 (en) | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
WO2007075554A2 (en) | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
JP5240739B2 (ja) | 2007-04-13 | 2013-07-17 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
AU2008221604B2 (en) | 2008-09-22 | 2010-04-22 | Commonwealth Scientific And Industrial Research Organisation | Temperature-responsive polymer particles in protein separation applications |
EP2419177A1 (de) | 2009-04-17 | 2012-02-22 | OSI Pharmaceuticals, LLC | Biologische marker zur vorhersage einer anti-krebs-antwort auf epidermale wachstumsfaktor-rezeptor-kinase-inhibitoren |
-
2006
- 2006-03-16 EP EP06738465A patent/EP1861715B1/de active Active
- 2006-03-16 US US11/377,530 patent/US8093011B2/en active Active
- 2006-03-16 CA CA002601157A patent/CA2601157A1/en not_active Abandoned
- 2006-03-16 DE DE602006016085T patent/DE602006016085D1/de active Active
- 2006-03-16 JP JP2008502016A patent/JP5085529B2/ja active Active
- 2006-03-16 WO PCT/US2006/009403 patent/WO2006101925A2/en active Application Filing
- 2006-03-16 AT AT06738465T patent/ATE477495T1/de not_active IP Right Cessation
-
2011
- 2011-12-12 US US13/374,132 patent/US9244058B2/en active Active
-
2015
- 2015-12-08 US US14/962,875 patent/US20160158235A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1861715A2 (de) | 2007-12-05 |
US9244058B2 (en) | 2016-01-26 |
US20060211060A1 (en) | 2006-09-21 |
JP2008533490A (ja) | 2008-08-21 |
JP5085529B2 (ja) | 2012-11-28 |
US20160158235A1 (en) | 2016-06-09 |
ATE477495T1 (de) | 2010-08-15 |
WO2006101925A3 (en) | 2007-02-01 |
WO2006101925A2 (en) | 2006-09-28 |
EP1861715B1 (de) | 2010-08-11 |
CA2601157A1 (en) | 2006-09-28 |
US20120157480A1 (en) | 2012-06-21 |
US8093011B2 (en) | 2012-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602006016085D1 (de) | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor | |
ATE533057T1 (de) | Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren | |
WO2008127718A3 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
WO2009045389A3 (en) | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors | |
WO2009045361A3 (en) | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors | |
Rossé et al. | Control of MT1-MMP transport by atypical PKC during breast-cancer progression | |
Gazzaniga et al. | Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis | |
Dickson et al. | High-level JAG1 mRNA and protein predict poor outcome in breast cancer | |
Adler et al. | Metastatic pathways in patients with cutaneous melanoma | |
Rodrigo et al. | Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas | |
DE602005019294D1 (de) | Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs | |
Luo et al. | Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma | |
Sun et al. | HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases | |
Torrisi et al. | HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17 | |
Gioacchini et al. | The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma | |
Yang et al. | Overexpression of the cancer stem cell marker CD117 predicts poor prognosis in epithelial ovarian cancer patients: Evidence from meta-analysis | |
Zhang et al. | Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma | |
Curtit et al. | Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay | |
Burdelski et al. | p16 upregulation is linked to poor prognosis in ERG negative prostate cancer | |
Liu et al. | MicroRNA‑10b expression in node‑negative breast cancer‑correlation with metastasis and angiogenesis | |
Qiao et al. | Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer | |
Song et al. | Combined detection of HER2, Ki67, and GSTP1 genes on the diagnosis and prognosis of breast cancer | |
Cercelaru et al. | E-cadherin, β-catenin and Snail immunoexpression in laryngeal squamous cell carcinoma | |
Ma et al. | Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion | |
EP2449383B1 (de) | Diagnoseverfahren zur vorhersage des krebsrekurrenzrisikos basierend auf histon-macroh2a-isoformen |